Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: A clinical practice guideline from the American College of Physicians

Clinical Guidelines Committee of the American College of Physicians

Research output: Contribution to journalArticle

Abstract

Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness of treatment with second-generation antidepressants versus nonpharmacologic treatments for major depressive disorder in adults. Methods: This guideline is based on a systematic review of published, English-language, randomized, controlled trials from 1990 through September 2015 identified using several databases and through hand searches of references of relevant studies. Interventions evaluated include psychotherapies, complementary and alternative medicines (including acupuncture,-3 fatty acids, S-adenosyl-L-methionine, St. John's wort [Hypericum perforatum]), exercise, and second-generation antidepressants. Evaluated outcomes included response, remission, functional capacity, quality of life, reduction of suicidality or hospitalizations, and harms. The target audience for this guideline includes all clinicians, and the target patient population includes adults with major depressive disorder. This guideline grades the evidence and recommendations using ACP's clinical practice guidelines grading system. Recommendation: ACP recommends that clinicians select between either cognitive behavioral therapy or second-generation antidepressants to treat patients with major depressive disorder after discussing treatment effects, adverse effect profiles, cost, accessibility, and preferences with the patient (Grade: strong recommendation, moderate-quality evidence).

Original languageEnglish (US)
Pages (from-to)350-359
Number of pages10
JournalAnnals of Internal Medicine
Volume164
Issue number5
DOIs
StatePublished - Mar 1 2016

Fingerprint

Major Depressive Disorder
Practice Guidelines
Guidelines
Antidepressive Agents
Physicians
Hypericum
Complementary Therapies
S-Adenosylmethionine
Patient Preference
Health Services Needs and Demand
Cognitive Therapy
Acupuncture
Therapeutics
Psychotherapy
Hospitalization
Language
Fatty Acids
Randomized Controlled Trials
Quality of Life
Databases

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder : A clinical practice guideline from the American College of Physicians. / Clinical Guidelines Committee of the American College of Physicians.

In: Annals of Internal Medicine, Vol. 164, No. 5, 01.03.2016, p. 350-359.

Research output: Contribution to journalArticle

@article{8d9a48f32bfc4ffbbd5468069c025dbd,
title = "Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: A clinical practice guideline from the American College of Physicians",
abstract = "Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness of treatment with second-generation antidepressants versus nonpharmacologic treatments for major depressive disorder in adults. Methods: This guideline is based on a systematic review of published, English-language, randomized, controlled trials from 1990 through September 2015 identified using several databases and through hand searches of references of relevant studies. Interventions evaluated include psychotherapies, complementary and alternative medicines (including acupuncture,-3 fatty acids, S-adenosyl-L-methionine, St. John's wort [Hypericum perforatum]), exercise, and second-generation antidepressants. Evaluated outcomes included response, remission, functional capacity, quality of life, reduction of suicidality or hospitalizations, and harms. The target audience for this guideline includes all clinicians, and the target patient population includes adults with major depressive disorder. This guideline grades the evidence and recommendations using ACP's clinical practice guidelines grading system. Recommendation: ACP recommends that clinicians select between either cognitive behavioral therapy or second-generation antidepressants to treat patients with major depressive disorder after discussing treatment effects, adverse effect profiles, cost, accessibility, and preferences with the patient (Grade: strong recommendation, moderate-quality evidence).",
author = "{Clinical Guidelines Committee of the American College of Physicians} and Amir Qaseem and Barry, {Michael J.} and Devan Kansagara and Forciea, {Mary Ann} and Denberg, {Thomas D.} and Cynthia Boyd and Chow, {R. Dobbin} and Nick Fitterman and Harris, {Russell P.} and Humphrey, {Linda L.} and Scott Manaker and Robert McLean and Sandeep Vijan and Timothy Wilt",
year = "2016",
month = "3",
day = "1",
doi = "10.7326/M15-2570",
language = "English (US)",
volume = "164",
pages = "350--359",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder

T2 - A clinical practice guideline from the American College of Physicians

AU - Clinical Guidelines Committee of the American College of Physicians

AU - Qaseem, Amir

AU - Barry, Michael J.

AU - Kansagara, Devan

AU - Forciea, Mary Ann

AU - Denberg, Thomas D.

AU - Boyd, Cynthia

AU - Chow, R. Dobbin

AU - Fitterman, Nick

AU - Harris, Russell P.

AU - Humphrey, Linda L.

AU - Manaker, Scott

AU - McLean, Robert

AU - Vijan, Sandeep

AU - Wilt, Timothy

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness of treatment with second-generation antidepressants versus nonpharmacologic treatments for major depressive disorder in adults. Methods: This guideline is based on a systematic review of published, English-language, randomized, controlled trials from 1990 through September 2015 identified using several databases and through hand searches of references of relevant studies. Interventions evaluated include psychotherapies, complementary and alternative medicines (including acupuncture,-3 fatty acids, S-adenosyl-L-methionine, St. John's wort [Hypericum perforatum]), exercise, and second-generation antidepressants. Evaluated outcomes included response, remission, functional capacity, quality of life, reduction of suicidality or hospitalizations, and harms. The target audience for this guideline includes all clinicians, and the target patient population includes adults with major depressive disorder. This guideline grades the evidence and recommendations using ACP's clinical practice guidelines grading system. Recommendation: ACP recommends that clinicians select between either cognitive behavioral therapy or second-generation antidepressants to treat patients with major depressive disorder after discussing treatment effects, adverse effect profiles, cost, accessibility, and preferences with the patient (Grade: strong recommendation, moderate-quality evidence).

AB - Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness of treatment with second-generation antidepressants versus nonpharmacologic treatments for major depressive disorder in adults. Methods: This guideline is based on a systematic review of published, English-language, randomized, controlled trials from 1990 through September 2015 identified using several databases and through hand searches of references of relevant studies. Interventions evaluated include psychotherapies, complementary and alternative medicines (including acupuncture,-3 fatty acids, S-adenosyl-L-methionine, St. John's wort [Hypericum perforatum]), exercise, and second-generation antidepressants. Evaluated outcomes included response, remission, functional capacity, quality of life, reduction of suicidality or hospitalizations, and harms. The target audience for this guideline includes all clinicians, and the target patient population includes adults with major depressive disorder. This guideline grades the evidence and recommendations using ACP's clinical practice guidelines grading system. Recommendation: ACP recommends that clinicians select between either cognitive behavioral therapy or second-generation antidepressants to treat patients with major depressive disorder after discussing treatment effects, adverse effect profiles, cost, accessibility, and preferences with the patient (Grade: strong recommendation, moderate-quality evidence).

UR - http://www.scopus.com/inward/record.url?scp=84959294611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959294611&partnerID=8YFLogxK

U2 - 10.7326/M15-2570

DO - 10.7326/M15-2570

M3 - Article

C2 - 26857948

AN - SCOPUS:84959294611

VL - 164

SP - 350

EP - 359

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -